Physician profile
Barry J Levitt
NPI 1528169596
$2,622.15
in general payments reported to CMS, 2019-2025
19 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $285 · 2021: $310 · 2022: $464 · 2023: $443 · 2024: $443 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,204.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $932.89 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $528.90 | 2020-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $236.78 | 2019-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $123.28 | 2019-2021 | |
| Braintree Laboratories, INC. | $122.33 | 2019 | |
| Merck Sharp & Dohme LLC | $94.29 | 2019-2023 | Dificid |
| Pfizer INC. | $92.09 | 2023-2025 | |
| Gilead Sciences, INC. | $81.03 | 2019-2023 | |
| Allergan, INC. | $79.27 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $70.42 | 2019-2024 | Linzess |
| Qol Medical, LLC | $60.41 | 2024 | Sucraid |
| Lilly USA, LLC | $58.36 | 2024-2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.78 | 2024 | Cyltezo |
| Regeneron Healthcare Solutions, INC. | $28.18 | 2025 | Dupixent |
| Vivus LLC | $20.18 | 2025 | Pancreaze |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $16.04 | 2022 | |
| Olympus America INC. | $15.61 | 2025 | Endoclot Phs |
| Evoke Pharma, INC. | $14.05 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Levitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.